APPLICATION
NDA011808
TYPE
NDA
ORIGINAL APPROVAL
1962-03-15
LATEST ACTION
2007-12-07
ROUTE
ORAL
DOSAGE FORM
CONCENTRATE, TABLET
MARKETING STATUS
Discontinued
Products
MELLARILDiscontinued
THIORIDAZINE HYDROCHLORIDE 100MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CONCENTRATE · ORAL
MELLARIL · ReferenceDiscontinued
THIORIDAZINE HYDROCHLORIDE 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
MELLARIL · ReferenceDiscontinued
THIORIDAZINE HYDROCHLORIDE 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
MELLARILDiscontinued
THIORIDAZINE HYDROCHLORIDE 30MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CONCENTRATE · ORAL
MELLARIL · ReferenceDiscontinued
THIORIDAZINE HYDROCHLORIDE 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
MELLARIL · ReferenceDiscontinued
THIORIDAZINE HYDROCHLORIDE 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
MELLARIL · ReferenceDiscontinued
THIORIDAZINE HYDROCHLORIDE 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
MELLARIL · ReferenceDiscontinued
THIORIDAZINE HYDROCHLORIDE 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
MELLARIL · ReferenceDiscontinued
THIORIDAZINE HYDROCHLORIDE 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
Approval history
2007-12-07Labeling · Supplement 106AP
2007-12-07Labeling · Supplement 159 · standardAP
2007-12-07Labeling · Supplement 97AP
2007-12-07Labeling · Supplement 157AP
2007-12-07Labeling · Supplement 171 · standardAP
2007-12-07Labeling · Supplement 28AP
2007-12-07Labeling · Supplement 93AP
2007-12-07Labeling · Supplement 139AP
2007-12-07Labeling · Supplement 153AP
2007-12-07Labeling · Supplement 85AP
2007-12-07Labeling · Supplement 145AP
2007-12-07Labeling · Supplement 77AP
2007-12-07Labeling · Supplement 137AP
2007-12-07Labeling · Supplement 129AP
2007-12-07Labeling · Supplement 59AP
2007-12-07Labeling · Supplement 61AP
2007-12-07Labeling · Supplement 107AP
2007-12-07Labeling · Supplement 174 · standardAP
2007-12-07Labeling · Supplement 166 · standardAP
2007-12-07Labeling · Supplement 105AP
2007-12-07Labeling · Supplement 164 · standardAP
2007-12-07Labeling · Supplement 29AP
2007-12-07Labeling · Supplement 96AP
2007-12-07Labeling · Supplement 148AP
2007-12-07Labeling · Supplement 101AP
2007-12-07Labeling · Supplement 154AP
2007-12-07Labeling · Supplement 160 · standardAP
2007-12-07Labeling · Supplement 152AP
2007-12-07Efficacy · Supplement 31AP
2007-12-07Labeling · Supplement 136AP
2007-12-07Labeling · Supplement 150AP
2007-12-07Labeling · Supplement 68AP
2007-12-07Labeling · Supplement 128AP
2007-12-07Labeling · Supplement 126AP
2007-12-07Labeling · Supplement 118AP
2001-06-15Manufacturing (CMC) · Supplement 177 · priorityAP
2001-03-28Manufacturing (CMC) · Supplement 179 · priorityAP
2000-06-19Labeling · Supplement 175 · standardAP
2000-03-01Manufacturing (CMC) · Supplement 176 · priorityAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.